National Institutes of Health (NIH)
U01 Research Project Cooperative Agreements
July 11, 2024 - Notice of Early Termination of NINDS/NCATS Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (PAR-22-184, U01 Clinical Trial Not Allowed). See Notice NOT-NS-24-120
April 19, 2023 - Notice of Change to Submission Requirements for PAR-22-184: Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed). See Notice NOT-NS-23-081
NOT-OD-23-012 Reminder: FORMS-H Grant Application Forms and Instructions Must be Used for Due Dates On or After January 25, 2023 - New Grant Application Instructions Now Available
NOT-OD-22-190 - Adjustments to NIH and AHRQ Grant Application Due Dates Between September 22 and September 30, 2022
This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. Through the support of trial readiness studies, NINDS expects to enhance the quality and increase the likelihood of success of clinical trials in these rare diseases.
30 days prior to application due date.
| Application Due Dates | Review and Award Cycles | ||||
|---|---|---|---|---|---|
| New | Renewal / Resubmission / Revision (as allowed) | AIDS | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
| August 18, 2022 | August 18, 2022 | Not Applicable | November 2022 | January 2023 | April 2023 |
| February 17, 2023 | February 17, 2023 | Not Applicable | July 2023 | October 2023 | December 2023 |
| August 17, 2023 | August 17, 2023 | Not Applicable | November 2023 | January 2024 | April 2024 |
| February 20, 2024 | February 20, 2024 | Not Applicable | July 2024 | October 2024 | December 2024 |
| August 19, 2024 | August 19, 2024 | Not Applicable | November 2024 | January 2025 | April 2025 |
All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Not Applicable
It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from NIH Guide for Grants and Contracts).
Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.
Applications that do not comply with these instructions may be delayed or not accepted for review.
Purpose
The purpose of this FOA is to fill gaps in clinical trial readiness for rare neurological and neuromuscular conditions that will soon have candidate therapeutics ready to test in clinical trials, but, due to the lack of validated clinical outcome assessment (COA) measures or biomarkers, the success of those trials may be compromised. This FOA invites researchers to submit applications for support of multi-site, prospective clinical projects that address critical needs for clinical trial readiness in these conditions. For this FOA, clinical trial readiness is defined as having established clinically valid biomarkers and clinical outcome assessment (COA) measures that are fit-for-purpose within a defined context of use in a planned clinical trial or trials, and clinical validation of these research tools is the final step before their implementation in trials. The National Institute of Neurological Disorders and Stroke (NINDS) and the National Center for Advancing Translational Sciences (NCATS) intend to enhance the quality and increase the likelihood of success of upcoming clinical trials in these diseases by supporting studies leading to trial readiness.
The initiative will promote partnerships among academic investigators, industry, and patient groups, and will encourage interactions with the Food and Drug Administration (FDA).
Terminology
This FOA uses terminology to describe this type of research as defined in the BEST (Biomarkers, EndpointS, and Other Tools) Resource, which was developed by the FDA-NIH Biomarker Working Group. Investigators are encouraged to use the terms below, where appropriate in their applications. Guidance to reviewers will include these definitions as a way to promote consistent evaluation of the applications. (See https://www.ncbi.nlm.nih.gov/books/NBK338448/ for reference to the BEST Resource's glossary for the following definitions.)
Biomarker A defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Molecular, histologic, radiographic, or physiologic characteristics are types of biomarkers. Categories of biomarkers include: Susceptibility/risk, diagnostic, monitoring, prognostic, predictive, pharmacodynamic/response, safety.
Clinical outcome assessment (COA) An assessment of an outcome that reflects how an individual feels, functions or survives. The four types of COAs are clinician-reported, observer-reported, patient-reported, and performance outcomes.
Context of Use (COU) A statement that fully and clearly describes the way the medical product development tool is to be used and the medical product development-related purpose of the use.
Concept In a regulatory context, the concept is the aspect of an individual’s clinical, biological, physical, or functional state, or experience that the assessment is intended to capture (or reflect).
Validation A process to establish that the performance of a test, tool, or instrument is acceptable for its intended purpose. For this FOA, the intended purpose should be the collection of data in a clinical trial that will be used to determine whether to move forward with the intervention being tested to a later stage trial or for regulatory approval. Applications in response to this FOA should focus on clinical validation. Biochemical and molecular biomarkers should have substantial data supporting analytical validation collected prior to submission of an application to this FOA.
- Analytical Validation A process to establish that the performance characteristics of a test, tool, or instrument are acceptable in terms of its sensitivity, specificity, accuracy, precision, and other relevant performance characteristics using a specified technical protocol (which may include specimen collection, handling and storage procedures). This is validation of the test s, tool s, or instrument’s technical performance, but is not validation of the item’s usefulness.
- Clinical Validation A process to establish that the test, tool, or instrument acceptably identifies, measures or predicts the concept of interest.
- Construct Validity A process to establish, using quantitative methods, the extent to which the relationships among items, domains, and concepts of a clinical outcome assessment conform to a priori hypotheses concerning logical relationships that should exist with other measures or characteristics of patients and patient groups.
- Content Validity A process to establish from qualitative research the extent to which the clinical outcome assessment instrument measures the concept of interest including evidence that the items and domains of an instrument are appropriate and comprehensive relative to its intended measurement concept, population, and use.
Background
The NINDS and NCATS support basic, translational and clinical research on a broad range of diseases that are defined as rare; diseases affecting fewer than 200,000 individuals in the United States (per the Rare Diseases Act of 2002). Clinical trials employ biomarkers and/or COA measures to determine whether interventions are safe, efficacious or effective in the study cohort(s). As defined above, COAs are measures of how a person feels, functions or survives, and biomarkers are characteristics of biological or pathological processes, or responses to interventions. Examples of COA measures for rare neurological or neuromuscular diseases are tests of motor function, cognitive ability or behavior. Biomarkers used in clinical trials can be categorized as predictive, prognostic or pharmacodynamic/response, depending on what is measured and how the data will be used in the trial. Examples of pharmacodynamic/response biomarkers for rare neurological or neuromuscular diseases are levels of disease relevant proteins in cerebrospinal fluid, or magnetic resonance imaging or spectroscopy approaches to measure the structure or composition of regions of the nervous system. Prior to launching clinical trials, the biomarker assays must be analytically validated, and the biomarker and COA measures must be clinically validated to establish their accuracy, sensitivity and reliability. Without appropriately validated research tools, clinical trials may be inconclusive or misleading. For some of the rare diseases within the mission of NINDS, preclinical translational research has resulted in the development of candidate therapeutics that may soon be ready for testing in trials, but clinical trial readiness may be lagging. The limited number of participants available for clinical trials in rare diseases places especially high demands on the sensitivity of biomarker and COA measures used to assess response to interventions. For these reasons, clinical trial readiness is considered a high research priority for rare neurological and neuromuscular diseases.
FDA published Draft Guidance on common issues in drug development for rare diseases. We encourage investigators to follow this guidance while developing a clinical trial readiness study.
Scope
Diseases appropriate for this FOA should lack critical components of trial readiness and should have candidate therapeutics that will be ready for testing in clinical trials by the time the trial readiness study is completed. Applications should propose clinical studies that verify that candidate COA measures and, if appropriate, biomarkers are optimized and ready for implementation within their context of use in upcoming trials. The applications should include a section (described below) that indicates what clinical trial(s) are being planned in the rare disease being studied. The project proposed must be necessary to achieve clinical trial readiness for the upcoming trial(s). Furthermore, when combined with existing clinical research tools and other ongoing research efforts, the proposed studies must be sufficient to fill the needs for validated biomarkers and COA measures for the upcoming trial(s) described in the application. Investigators are encouraged to use or modify existing resources, validate existing tools in specific rare disease populations, or add components to existing disease-specific tools (such as symptom scales).
Because of the large number of rare diseases within the mission of the NINDS and limited funds for this program, it is unlikely that more than one study will be funded for any disease. Therefore, investigators are encouraged to form collaborations with other researchers in the same disease area; reach consensus on the biomarkers and COA measures needing validation for use in upcoming clinical trials; and submit one application, rather than competing or complimentary applications.
Applications responsive to this FOA must propose multisite, prospective clinical studies aimed at validating COA measures or scales and may also propose clinical validation of biomarkers. Studies proposing only biomarker studies should consider applying to the NINDS FOAs on biomarkers.
Examples of studies intended to be supported through this FOA include, but are not limited to, the following:
- Studies aimed at the validation of clinician-reported, observer-reported, patient-reported, and/or performance outcomes with defined contexts of use in specific rare disease populations.
- Studies aimed at the validation of COA measures and one or more biomarker(s) that can be of any category relevant to clinical trials including safety, predictive, prognostic or pharmacodynamic/response.
- Studies to validate candidate biomarkers by analyzing the correlation of biomarkers with COA measure data collected in the same cohort.
- Studies that, through the validation of COA measures or biomarkers, collect the data necessary to determine appropriate participant inclusion/exclusion criteria for upcoming clinical trials.
- Studies that, through the validation of COA measures or biomarkers, collect the data needed for accurate power calculations or determining the appropriate duration of upcoming clinical trials.
- Validation studies that demonstrate responsiveness of biomarkers or COAs through the observation of patients who are receiving treatment as part of their clinical care.
- Ancillary studies that aim to validate COA measures or biomarkers by adding them to ongoing clinical studies (or trials) supported through other sources of funding.
Applications Not Responsive to this FOA:
- Applications that propose animal studies
- Applications that propose a clinical trial or trials
- Applications proposing studies of disease pathophysiology or disease mechanisms
- Applications proposing studies of diseases/conditions other than rare diseases (200,000 or fewer patients in the U.S.)
Non-responsive applications will not be reviewed.
This FOA will support well justified applications for testing of biomarkers or outcome measures, which include justification that assays and methods for measurement are ready for use in a multi-site study at the time of application. For biochemical or molecular biomarkers, this justification should describe accuracy, precision, analytical sensitivity, analytical specificity including interfering substances, dynamic range, and expected normal values. For imaging, radiological, or physiological biomarkers, the justification should provide preliminary data on the accuracy, reproducibility, sensitivity, and specificity as determined by study of a patient cohort (but not necessarily in the same rare disease).
An appropriate study could start with a small, manageable set of well-justified candidate biomarkers, and based on data acquired during the study, be narrowed down to one or a few appropriate biomarkers to validate for use in a clinical trial.
Studies of biomarker discovery or early characterization should seek funding through the Discovery of Biomarkers and Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional) FOA.
Applications that propose only to maintain patient registries will not be considered for funding. NINDS does not intend to provide support to maintain or acquire additional data on study participants beyond the end of the clinical trial readiness grant.
Applications that request support for infrastructure to establish new clinical trial networks are beyond the scope of this FOA. Applicants should leverage existing resources such as existing rare disease-focused networks (e.g., the Rare Disease Clinical Research Network (RDCRN)).
Leveraging Existing Research Resources
Applicants should leverage existing research resources for their clinical trial readiness studies. Such resources may include existing clinical research networks such as RDCRN, NeuroNEXT, or other existing networks that have successfully conducted studies of rare diseases. Also, applicants should leverage existing research resources to streamline multi-center studies, such as the SMART IRB. Applicants should consider using the services of the Biospecimen Exchange for Neurological Disorders (BioSEND) or the NINDS Human Cell and Data Repository (NHCDR) to bank and distribute biological specimens collected from participants in these trial readiness studies. Leveraging the resources and support from advocacy groups, private research foundations, academic institutions, other government agencies, and the NIH Intramural program are also encouraged.
Studies are also encouraged to leverage the resources of ongoing clinical trials or longitudinal studies supported through other Federal or private funds. Researchers may consider collecting data to validate new or improved COA measures or biomarkers as ancillary studies to ongoing clinical trials or longitudinal studies. Use of existing research resources, if any, should be documented in the budget section.
See Section VIII. Other Information for award authorities and regulations.
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.
Resubmission
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.
Not Allowed: Only accepting applications that do not propose clinical trials.
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Application budgets are limited to $750,000 in direct costs in any project year (exclusive of facilities and administrative costs of subcontractors with collaborating organizations).
The maximum project period is 5 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.
1. Eligible Applicants
Higher Education Institutions
- Public/State Controlled Institutions of Higher Education
- Private Institutions of Higher Education
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
- Hispanic-serving Institutions
- Historically Black Colleges and Universities (HBCUs)
- Tribally Controlled Colleges and Universities (TCCUs)
- Alaska Native and Native Hawaiian Serving Institutions
- Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)
Nonprofits Other Than Institutions of Higher Education
- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
For-Profit Organizations
- Small Businesses
- For-Profit Organizations (Other than Small Businesses)
Local Governments
- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized)
Federal Government
- Eligible Agencies of the Federal Government
- U.S. Territory or Possession
Other
- Independent School Districts
- Public Housing Authorities/Indian Housing Authorities
- Native American Tribal Organizations (other than Federally recognized tribal governments)
- Faith-based or Community-based Organizations
- Regional Organizations
- Non-domestic (non-U.S.) Entities (Foreign Institutions)
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Applicant organizations
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
- System for Award Management (SAM) Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
- NATO Commercial and Government Entity (NCAGE) Code Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.
- Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.gov registration process. SAM registrations prior to fall 2021 were updated to include a UEI. For applications due on or after January 25, 2022, the UEI must be provided on the application forms (e.g., FORMS-G); the same UEI must be used for all registrations, as well as on the grant application.
- eRA Commons - Once the unique organization identifier (UEI after April 2022) is established, organizations can register with eRA Commons in tandem with completing their full SAM and Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
- Grants.gov Applicants must have an active SAM registration in order to complete the Grants.gov registration.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. See, Reminder: Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities, NOT-OD-22-019.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
2. Cost Sharing
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
3. Additional Information on Eligibility
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications)
1. Requesting an Application Package
The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
2. Content and Form of Application Submission
It is critical that applicants follow the instructions in the Research (R) Instructions in the SF424 (R&R) Application Guide except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.Letter of Intent
Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.
By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:
- Descriptive title of proposed activity
- Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
- Names of other key personnel
- Participating institution(s)
- Number and title of this funding opportunity
The letter of intent should be sent to:
Glen H. Nuckolls PhD
Telephone: 301-496-5876
Email: [email protected]
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing (DMS) Plan will be attached in the Other Plan(s) attachment in FORMS-H and subsequent application forms packages. For due dates on or before January 24, 2023, the Data Sharing Plan and Genomic Data Sharing Plan GDS) will continue to be attached in the Resource Sharing Plan attachment in FORMS-G application forms packages.
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
R&R or Modular Budget
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Other Plan(s):
Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H and subsequent application forms packages. For due dates on or before January 24, 2023, the Data Sharing Plan and Genomic Data Sharing Plan GDS) will continue to be attached in the Resource Sharing Plan attachment in FORMS-G application forms packages.
All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Rare Disease Status - The Significance section of the Research Strategy must include a paragraph with the heading Justification of Rare Disease . This section should provide a justification that the disease/condition being studied is rare in the U.S. This section may include one or more references confirming that the prevalence of the disease/condition that is the primary focus of the research application is 200,000 or fewer patients in the U.S. If the disease/condition has been granted orphan status by the FDA, provide this information in the justification. If it is a rare variant or subset of a more common condition, provide a justification for focusing a trial readiness study on this variant. Describe the scientific basis for separating biomarker/COA validation for this rare variant or subset from that of the common condition.
Need for Clinical Trial Readiness - The Significance section of the Research Strategy must also include a further subsection with the heading Urgent Need for Clinical Trial Readiness . This subsection should describe the need for conducting the trial readiness study at this time. Applicants should describe the clinical trial design issues (e.g., biomarker or COA validation) that will be addressed by this trial readiness study. Describe the potential impact of the proposed studies in addressing significant needs in the design and increasing the likelihood of success of upcoming clinical trials. Explain how the gender, age and demographics of the study poplulation are appropriate for the goal of readiness for upcoming trials.
This section should also contain the following:
- A brief description of the state of development of candidate therapeutics or devices for this rare disease (even if the current applicants are not involved in the development of those therapeutics/devices).
- Timelines for the advance of therapeutics/devices to clinical trials.
- A brief description of the clinical trial(s) that would be enabled by the results of this trial readiness study. Provide letters of support (below) from the researchers who expect to conduct upcoming trials.
- Include a brief description of the currently available COA measures and/or biomarkers. If appropriate for the proposed study, describe how the study will result in advancements over the currently available measures/biomarkers. If the current measures/biomarkers are considered inadequate or insufficiently developed for use in upcoming trials, describe their limitations and how those limitations may compromise the success of upcoming trials. If the proposed trial readiness study is ancillary to an ongoing clinical trial or longitudinal study, describe that study and provide a letter of support (below) from the study's lead PD(s)/PI(s). Explain how the trial readiness study will lead to improvements in the design of future trials above that of the ongoing study.
- Briefly describe the role of companies or voluntary health organizations that are currently engaged or potentially available to contribute to clinical trial readiness studies or clinical trials for this disease, if applicable.
Biomarkers and Their Context of Use
If biomarker validation is proposed, the approach section of the application must contain a subsection with the heading Biomarkers and Their Contexts of Use . This section should describe each biomarker that will be tested for validation and the context of use (COU). The COU should briefly explain how, when and why the biomarker is to be used in a clinical trial.
Biochemical/molecular biomarkers must have analytical validation before applying for a clinical trial readiness award through this program. Applications must include a table listing each biochemical/molecular biomarker to be tested for clinical validation, the intended use (e.g., diagnostic, predictive, treatment response, pharmacodynamic), the method of the assay (e.g., mass spectrometry, ELISA, surface plasmon resonance), the sensitivity, dynamic range and expected normal values. Other characteristics of the assay such as specificity, precision, interfering substances, etc. should also be described in the text of this subsection. Describe what a graph of each biomarker measurement over the time course of the disease is expected to show (e.g., linearly decreasing measurement, periodic fluctuations, etc.) and the expected relationship of the biomarker to COA measures.
For imaging, radiological, or physiological biomarkers, the justification should provide preliminary data on the accuracy, reproducibility, sensitivity, and specificity as determined by study of a patient cohort (but not necessarily in the same disease). Describe the equipment (i.e., instrument manufacturer and model) and expertise available at each clinical site for measuring the biomarker(s). Plans for the training of personnel at each site in the use of the standardized protocols, data quality control strategies, reference standards and approaches for verifying instrument calibration at the clinical sites should also be described as appropriate.
Clinical Outcome Assessment Measures
COA measures can be clinician-, observer-, or patient-reported, or performance outcomes. Applications must provide a list of each COA measure that the study aims to clinically validate. Describe the construct validity (i.e., hypothesized relationship with other disease characteristics) and content validity (i.e., extent to which the COA measures the concept of interest) for each COA measure (also see Definitions section above). Describe plans for analysis of test-retest and inter-rater reliability. Describe Rasch analysis for COA measure optimization if appropriate.
Statistical Analysis Plans
A section describing the plans for statistical analysis of the data and tests for validation of biomarkers/COA (s) must be included in the application. Explain the decision for selecting the statistical analysis methods and how the methods selected are best suited for this rare disease study what methods were considered; why were the proposed methods chosen. Describe sample size considerations for validating the biomarkers and COA(s). Statistical analysis of convergent validity of COA measures and biomarkers is often an important component of trial readiness studies. Describe which biomarkers and COA measures will be tested for convergent validity, if appropriate for the study. Povide justification that the study is adequately powered and the proposed study population is appropriate to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results. Justify the duration of the study.
Existing Clinical Networks
For ancillary studies, briefly describe the aims of the parent study and the timeline of the parent study relative to the proposed ancillary study. The application should discuss the additional burden to the participants of the parent study and whether consent obtained from the participants is adequate to cover the ancillary study or if additional consent must be obtained. (See also Letters of Support)
Advisory Committee
The Approach section of the Research Strategy must include a further subsection with the heading Advisory Committee . This subsection should describe plans for establishing an advisory committee for the study, composed of at least five members. The members should include researchers not directly involved in the study, either from academics or from industry, who may lead future clinical trials that would be enabled by this trial readiness study. Researchers conducting similar studies in other diseases may also have the appropriate expertise for this committee. This subsection should also describe plans for an initial meeting of study investigators with the committee to seek comments and suggestions on the design of the study and approval of the study protocol, before enrollment begins. Also, describe plans for regular meetings with the committee to review progress and solicit advice on course corrections. Describe how the advice from the committee will be incorporated into the management of the study. The Advisory Committee will not be responsible for data and safety monitoring (see Data and Safety Monitoring section below). The NIH Project Scientist for the Cooperative Agreement should be invited to participate in all meetings of the committee but would not be a voting member.
The perspectives of patients and other study participants or their parents/guardians must be considered in the design and conduct of the study to enhance recruitment and retention and minimize participant burden. The Advisory Committee should include community engagement, one or more patients or patient advocates. Furthermore, researchers should solicit feedback from study participants and use this information to guide the study. Methods for soliciting feedback from the participants may include surveys, or conducting group listening sessions. The Approach section should describe plans for soliciting this input, the methods to be used, the frequency of collecting feedback from patients/participants, and how this information will be used in the management of the study. The Approach section should also include potential ethical issues and the process for obtaining informed consent or assent.
Project Milestones and Timelines
In this subsection under Approach, applicants must describe milestones to be used for measuring success in achieving each of the research plan’s aims. Explain how the study is designed to conduct the research efficiently. Specify the quantitative criteria for measuring success and related rationale. One or more milestones should be used for each aim. Specify the timeline for each milestone. There should be at least one milestone each year. Consider including an interim data analysis and provide quantitative criteria for go/no-go decisions for continuing the study of each biomarker and/or COA. This is especially encouraged for any invasive biomarkers such as those involving longitudinal lumbar punctures.
If international sites are proposed, the milestones and timelines should address the complexity of executing the clinical study in accordance with policies and regulations at each site (e.g., data sharing, ethical implications, etc.).
Examples of milestones include, but are not limited to the following:
- Go/no go decision points regarding biomarker or COA sensitivity, reliability and responsiveness
- Institutional Review Board (IRB) and other regulatory approvals (applicants are encouraged to use a central IRB)
- Certification of clinical sites regarding the training of personnel on the study protocol, calibration of instruments, implementation of data management and safety monitoring protocols, etc.
- Approval of the research protocol by the Advisory Committee
- Patient enrollment (including gender, race and ethnicity, children) and clinic visit milestones for each grant year.
For biomarker and COA measure validation investigators are encouraged to request a Critical Path Innovation Meeting (CPIM) with the FDA Center for Drug Evaluation and Research (CDER) for drug products, or other similar earlier interaction meetings with other FDA Centers, where applicable, to seek FDA input into the proposal validation or study proposal. If applicable, a CPIM meeting could be one of the study milestones.
Include a timeline that indicates IRB approval(s), meetings of the Advisory Committee, staging of patient visits, and expected completion for each of the milestones. Also describe the time frame of planning for clinical trials that will utilize the resulting products of the trial readiness study.
Applicants proposing multi-site non-exempt humans subjects research are required to use a single IRB.
Letters of Support
If appropriate, provide a letter of support from the leader(s) of the existing clinical research network that will conduct the trial readiness study that indicates the sites involved in the network, relevant resources and study infrastructure, and an estimate of the number of eligible, relevant rare disease patients accessible through the network. For ancillary studies, provide a letter of support from the PD/PI of the parent study that includes a brief description of the aims of the parent study and indicates the timeline of the parent study relative to the proposed ancillary study.
Use of Common Data Elements in NIH-funded Research
Many NIH ICs encourage the use of common data elements (CDEs) in basic, clinical, and applied research, patient registries, and other human subject research to facilitate broader and more effective use of data and advance research across studies. CDEs are data elements that have been identified and defined for use in multiple data sets across different studies. Use of CDEs can facilitate data sharing and standardization to improve data quality and enable data integration from multiple studies and sources, including electronic health records. NINDS has identified CDEs for many clinical neurological/neuromuscular diseases and types of outcomes (e.g., patient-reported outcomes). NINDS provides resources for CDEs (https://www.commondataelements.ninds.nih.gov/#page=Default) to assist investigators in developing protocols, case report forms, and other instruments for data collection. Investigators are encouraged to consult the NINDS CDE website and describe in their applications any use they will make of these CDEs in their projects.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.
The following modifications also apply:
- All applications, regardless of the amount of direct costs requested for any one year, are expected to include a plan for the sharing of clinical data and biospecimens, consistent with achieving the goals of the program.
- This Data/Resource Sharing Plan should include a timeline for publications and access to additional study data and biospecimens. It should describe the process for evaluating requests for access to the data and/or biospecimens, and the expected time from when the request is received to when the sharing of data/biospecimens is achieved. If using BioSEND or NHCDR briefly describe how this resource will be used to bank and distribute biospecimens. A table of the requests should be included in annual progress reports and provided to the Advisory Committee, including the requester's name, nature of the request, date received, description and date of follow-through on each request.
The following modifications also apply:
- Protocols describing the procedures for measuring the biomarkers or evaluating the COA proposed are encouraged.
- If an ancillary study is proposed, the most recently approved protocol for the parent clinical trial or longitudinal study and the consent form for the parent study are required.
- If the investigators have had communications with the FDA through a Critical Path Innovation Meeting or other meeting(s) about the proposed biomarker(s) or COA measure(s), a summary of the meeting or documentation of guidance from the FDA is required.
- If the proposed study involves the expanded access regulatory pathway, protocols used for expanded access studies or documentation submitted to FDA to initiate and amend expanded access protocols are required.
When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered Yes to the question Are Human Subjects Involved? on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record.
Study Record: PHS Human Subjects and Clinical Trials Information
All instructions in the SF424 (R&R) Application Guide must be followed.
Section 2 - Study Population Characteristics
Additional Requirements for Inclusion, Recruitment and Retention
A goal of this initiative is to support studies that lead to findings that are applicable to all people affected by the rare disease being studied. Therefore, it is important that the sex/gender, race, ethnicity and age of the participants appropriately represent the population of people living with the studied condition in the U.S. Applications may request personnel effort, support for study participant travel/meals and other budget items within the overall budget cap to ensure that this goal of appropriate inclusion is met.
All applications must follow the instructions G.500 PHS Human Subjects and Clinical Trials Information with additional instructions specific to this FOA.
In sections 2.4 Inclusion of Women andMinorities and 2.5 Recruitment and Retention Plan applications must address the following points in addition to the G.500 instructions.
2.4 Inclusion of Women and Minorities
Application attachment Inclusion of Women and Minorities additional requirements:
-
- Provide data if available on the demographics of individuals affected by the condition under study in the catchment area for the clinic sites proposed in the application.
- Provide annual milestones for enrollment including numbers by sex/gender, race and ethnicity.
- Identify the person/people in the research team that will carry out the proposed outreach and their qualifications or relevant abilities such as fluency in languages other than English and/or cultural sensitivity.
2.5 Recruitment and Retention Plan
Application attachment Recruitment and Retention Plan additional requirements
- Describe how the proposed recruitment and retention plan is designed to overcome obstacles to study participation. Strategies to overcome obstacles include but are not limited to the following:
- Broaden the eligibility criteria as appropriate so as not to exclude potential participants for reasons that are unlikely to affect the outcomes of the study.
- Minimize the burden of participating in the study by reducing the frequency and/or duration of clinic visits and overall time required.
- Select study sites with ample numbers and diversity of potential study participants.
- Select study sites that minimize the travel of study participants.
- Provide support for study participant transportation, accommodations and parking as needed.
- Provide daycare for family members during study visits.
- Allow for clinic visits in evenings or during weekends.
- Integrate remote data collection such as smartphone apps or wearables into the study design while also taking into consideration the need for access to broadband communication networks in rural areas.
- Establish recruitment, enrollment and/or data collection sites in the community at locations that are convenient, familiar and trusted by potential study participants.
- Have validated translations of consent forms and other relevant study documents available in languages that help ensure achievement of the planned enrollment.
- Include study personnel who are bilingual and culturally sensitive to the planned enrollment population. Consider enlisting the help of community ambassadors to build trust in the communities of potential study participants.
- In addition to the primary plan for recruiting sex/gender, racial, and ethnic group members, provide alternative/back-up strategies to be used if enrollment significantly deviates (more than 20% of any category for each annual milestone) from the planned numbers according to sex/gender, race or ethnicity. Back-up plans may, for example, propose to add research sites with access to additional individuals that are understudied in the enrollment.
- Describe what other research studies may be competing for recruitment of the same patient population at the same clinic sites that are proposed in the application. Describe plans for communicating to potential study participants the options available to them.
Delayed Onset Study
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Foreign Institutions
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
3. Unique Entity Identifier and System for Award Management (SAM)
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
5. Intergovernmental Review (E.O. 12372)
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.
Important reminders:
All PD(s)/PI(s) must include their eRA Commons ID in the Credential fieldof the Senior/Key Person Profile form. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the unique entity identifier (UEI) provided on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant and/or non-responsive will not be reviewed.
Requests of $500,000 or more for direct costs in any year
Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact the Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.
Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.
1. Criteria
Note: Effective for due dates on or after January 25, 2023, the Data Sharing Plan and Genomic Data Sharing Plan (GDS) as part of the Resource Sharing Plan will not be evaluated at time of review.
Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.
For this particular announcement, note the following:
Applications must contain the special subsections "Justification of Rare Disease" and "Urgent Need For Clinical Trial Readiness" under "Significance", and "Biomarkers And Their Contexts of Use", "Advisory Committee", and "Milestone And Timelines" under "Approach". The attachments on Inclusion of Women andMinorities and Recruitment and Retention Plan also have additional required material. Reviewers will consider special review criteria described below for each of these subsections.
Overall Impact
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
Scored Review Criteria
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Significance
Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?
- How strong is the scientific justification in the application that the disease or condition meets the criteria of being rare (fewer than 200,000 patients in the U.S., and/or documentation of FDA orphan status)? If the study focuses on a rare subcategory of a common disease/condition, how strong is the justification for the need to address clinical trial readiness specifically for this subcategory?
- If the application is for a rare variant or subset of a more common condition, how strong is the justification that a separate clinical trial readiness activity is needed to focus on this rare form?
- How well does the project fill a gap in preparing for an upcoming clinical trial or trials? How does this application address a gap in outcome measure and/or biomarker clinical validation?
- How clearly does the application describe the Context of Use (COU) of the biomarker or outcome measure such that it will enable the design of upcoming clinical trials?
- How will the readiness study increase the likelihood of success of upcoming trials?
- How does this proposed study relate to other ongoing efforts for this rare disease? Consider whether there is overlap with ongoing efforts or missed opportunities for coordinated efforts in the same rare disease?
- How strong is the justification that there is urgency and that there will be candidate therapeutics ready for testing in clinical trials at the time of completion of the proposed trial readiness study?
- For studies that are ancillary to an ongoing clinical trial or longitudinal study, how will it advance the design of future trials beyond that of the parent study? How will the additional burden of the ancillary study affect the participants in the parent study? How does the consent obtained for participation in the parent study relate to consent for the ancillary study?
Investigator(s)
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?
Innovation
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?
Approach
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?
- How likely are the proposed studies to establish clinically validated biomarkers and/or COA measures with well-defined contexts of use in upcoming clinical trials?
- How well will the milestones measure success in achieving the aims of the application? How feasible are the milestones for participant enrollment relative to the timeline for completing the aims within the term of the grant?
- If an interim analysis is proposed, how effectively will the milestones for the performance of COA measures or biomarkers establish appropriate go/no-go decision points in preparing for clinical trials?
- How well prepared for use in this study are the assays for biochemical or molecular biomarkers, or the methods for measuring imaging, radiological or physiological biomarkers, and/or COAs?
- How well does the application describe a plan to establish and meet regularly with the Advisory Committee? Are there appropriate plans to incorporate the advice from this committee to the management of the study?
- How well does the application describe plans for including the comments of patients and other study participants or their parents/guardians in the management of study recruitment, retention and the minimization of participant burden?
- How strong is the justification that the planned enrollment will appropriately represent the sex/gender, race, ethnicity and age of the population of individuals in the U.S. affected by the disease being studied?
- How likely are the recruitment and retention strategies provided in the application to achieve the planned enrollment?
- Do the recruitment and retention plans describe primary and back-up strategies that are likely to reduce obstacles to study participation and ensure enrollment of appropriate diverse cohort(s) of participants?
- Is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the study appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group) and duration of the study, appropriate and well justified?
- Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate?
- Are the plans to standardize, assure quality of, and monitor adherence to, the study protocol and data collection appropriate? Does the application propose to use existing available resources, as applicable?
- Are planned analyses and statistical approach appropriate for the proposed study design given the limited number of participants eligible for this rare disease study? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?
- Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?
- Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?
Environment
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?
- Do the clinical sites provide access to a sufficient number of patients with the rare disease to support enrollment for the study?
-
How well does the application describe the demographics of potential study participants at the recruitment sites and is there justification that the sex/gender, race and ethnicity of the actual enrollment will match the planned enrollment based on availability of potential participants?
- How strong is the justification that all of the participating clinical sites have the appropriate expertise and equipment for measuring COAs and analyzing appropriate biomarkers?
- If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the study proposed?
- Does the application adequately address the capability and ability to conduct the study at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?
- If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical study in accordance with policies and regulations at each site (e.g., data sharing, ethical implications, etc.)?
- Is there evidence of the ability of the individual sites to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and (4) operate within the proposed organizational structure?
Additional Review Criteria
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Protections for Human Subjects
For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
Inclusion of Women, Minorities, and Individuals Across the Lifespan
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
Vertebrate Animals
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Biohazards
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
Resubmissions
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
Renewals
Not applicable
Revisions
Not applicable
Note: Effective for due dates on or after January 25, 2023, the Data Sharing Plan and Genomic Data Sharing Plan (GDS) as part of the Resource Sharing Plan will not be evaluated at time of review.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Applications from Foreign Organizations
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Select Agent Research
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Resource Sharing Plans
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).
Authentication of Key Biological and/or Chemical Resources:
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Budget and Period of Support
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
2. Review and Selection Process
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NINDS, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications will receive a written critique.
Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
- Scientific and technical merit of the proposed project as determined by scientific peer review.
- Availability of funds.
- Relevance of the proposed project to program priorities.
3. Anticipated Announcement and Award Dates
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
1. Award Notices
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.
Recipients must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
2. Administrative and National Policy Requirements
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:
- Federalwide Research Terms and Conditions
- Prohibition on Certain Telecommunications and Video Surveillance Services or Equipment
- Acknowledgment of Federal Funding
If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.
Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex (including gender identity , sexual orientation, and pregnancy). This includes ensuring programs are accessible to persons with limited English proficiency and persons with disabilities. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html
HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.
- Recipients of FFA must ensure that their programs are accessible to persons with limited English proficiency. For guidance on meeting the legal obligation to take reasonable steps to ensure meaningful access to programs or activities by limited English proficient individuals see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/fact-sheet-guidance/index.html and https://www.lep.gov.
- For information on an institution’s specific legal obligations for serving qualified individuals with disabilities, including reasonable accommodations and making services accessible to them, see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html.
- HHS funded health and education programs must be administered in an environment free of sexual harassment, see https://www.hhs.gov/civil-rights/for-individuals/sex-discrimination/index.html. For information about NIH's commitment to supporting a safe and respectful work environment, who to contact with questions or concerns, and what NIH's expectations are for institutions and the individuals supported on NIH-funded awards, please see https://grants.nih.gov/grants/policy/harassment.htm.
- For guidance on administering programs in compliance with applicable federal conscience protection and associated anti-discrimination laws see https://www.hhs.gov/conscience/conscience-protections/index.html and https://www.hhs.gov/conscience/religious-freedom/index.html.
Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.
In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 Federal awarding agency review of risk posed by applicants. This provision will apply to all NIH grants and cooperative agreements except fellowships.
The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Parts 75, 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the U01 cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the purpose of the NIH is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility reside with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have primary responsibility for:
- Defining research objectives and approaches.
- Planning, conducting, analyzing, and publishing results, interpretations, and conclusions of their studies and for providing overall scientific and administrative leadership for the Research Project.
- Supervising the clinical study with a consistent emphasis on collaborative interactions among PD(s)/PI(s), advisory and steering committees, and NIH representatives.
- Retaining custody of and maintaining primary rights to data and software developed under this award, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.
NIH Staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
- NIH staff involvement will include oversight of the IRB-approved protocol by the NIH Program Official, documentation of adequate serious adverse event management and reporting, and regular communications with the PD/PI and staff; additional involvement generally includes participation in meetings of the advisory committee. Specifically:
- An NIH Project Scientist working with the PD/PI will develop milestones for the study. Failure to meet the agreed-upon milestones may result in reduced funding or early termination of the cooperative agreement. The NIH retains the option to obtain periodic external peer reviews of progress.
- The NIH Project Scientist will function as one of several co-investigators, collaborating and interacting as necessary with the PD(s)/PI(s) in accomplishing the overall goals of the Research Program.
- In addition, an NIH Program Official will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.
- The NIH Program Official and Project Scientist should also be invited to participate in meetings of the steering committee and the Scientific Advisory Committee.
- If the proposed study should involve interaction with the FDA regarding biomarkers or outcome measures, the NIH Project Scientist and/or Program Official(s) will be present at any meetings held with the FDA related to this NIH-funded protocol.
Applicants are encouraged to consult with NIH Scientific/Research Staff early on during the planning for an application. This early contact will provide an opportunity to discuss and clarify NIH policies and guidelines, including the scope of the project relative to the NIH mission and the intent of this FOA. These discussions also provide important information and guidance on how to develop an appropriate timeline and milestone plan, which are subject to peer review under this program.
As with any award, even during the period recommended for support, continuation is conditional upon satisfactory progress. If at any time, recruitment falls significantly below the projected milestones for recruitment, the NIH will consider ending support and negotiating a phase-out of the award. The NIH retains the option to obtain periodic external peer reviews of progress. Milestones will be established by the NIH prior to the award of the grant based on recommendations from the primary review group. Feasibility milestones will be defined at the start of each trial and will be monitored closely by the NIH Program Official. Achievement of these milestones will be evaluated by NIH prior to releasing funding for each year of the award and failure to achieve these milestones may lead to study termination.
Areas of Joint Responsibility include:
- Clarifying, negotiating, and finalizing the milestones and timelines.
Dispute Resolution
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16. Final decisions made by NIH regarding a discontinuation are not appealable.
Data Management and Sharing
Note: The NIH Policy for Data Management and Sharing is effective for due dates on or after January 25, 2023.
Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.
3. Reporting
When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.
In addition to the information described in the RPPR instructions, awardees should also include the following information in each progress report:
- A summary of any recommendations from the Advisory Committee if a meeting occurred during the year of reporting.
- The Resource Sharing Plan should include a timeline for publications and access to additional study data and biospecimens. It should describe the process for evaluating requests for access to the data and/or biospecimens, and the expected time from when the request is received to when the sharing of data/biospecimens is achieved. If using BioSEND, briefly describe the process for evaluating request used by this resource. A table of the requests for study data or biospecimens received from other researchers including the requester's name, nature of the request, date received, description and date of follow-through on the requests.
A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 Award Term and Conditions for Recipient Integrity and Performance Matters.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)
Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: [email protected] (preferred method of contact)
Telephone: 301-480-7075
Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: [email protected]
Glen H. Nuckolls, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-5745
Email: [email protected]
Alice Chen
National Center for Advancing Translational Sciences (NCATS)
Phone: (301) 827-2015
E-mail: [email protected]
Ana Olariu, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9223
Email: [email protected]
Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: [email protected]
David Madoo
National Center for Advancing Translational Sciences (NCATS)
Phone: 301-761-6703
Email: [email protected]
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 2 CFR Part 200, 42 CFR Part 52, and 45 CFR Part 75.
and Human Services (HHS)
